Spellman v. Takeda Development Center Americas, Inc.

CourtDistrict Court, E.D. New York
DecidedMarch 31, 2021
Docket2:19-cv-05608
StatusUnknown

This text of Spellman v. Takeda Development Center Americas, Inc. (Spellman v. Takeda Development Center Americas, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Spellman v. Takeda Development Center Americas, Inc., (E.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT For Online Publication Only EASTERN DISTRICT OF NEW YORK -------------------------------------------------------------X DAVID SPELLMAN,

Plaintiff, ORDER -against- 19-CV-5608 (JMA)(ARL)

TAKEDA DEVELOPMENT CENTER AMERICAS, INC., TAKEDA PHARMACEUTICALS AMERICA, INC., AND TAKEDA PHARMACEUTICALS INTERNATIONAL, INC.,

Defendants. -------------------------------------------------------------X AZRACK, United States District Judge: Before the Court is a motion by plaintiff David Spellman (“Plaintiff”) to voluntarily dismiss this case without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(2). For the following reasons, the Court grants Plaintiff’s motion to dismiss without prejudice. I. BACKGROUND On September 11, 2019, Plaintiff, proceeding pro se, commenced this action in the Supreme Court of the State of New York, Suffolk County against defendants Takeda Development Center Americas, Inc., Takeda Pharmaceuticals America, Inc. (“Takeda America”), and Takeda Pharmaceuticals International, Inc. (collectively, “Defendants”). Plaintiff alleges he suffered injuries from use of the prescription medication, Entyvio, which Defendants “designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and distributed.” (Compl., ECF No. 1-1.) Plaintiff brings claims for negligence, strict products liability, breach of express and implied warranties, fraudulent concealment, negligent misrepresentation, and consumer fraud in violation of New York General Business Law §§ 349 and 350. (Id.) On October 3, 2019, Defendants removed the action to this Court on the basis of diversity jurisdiction. (ECF No. 1.) On October 10, 2019, Takeda America filed an answer. (ECF No. 7.) On October 23, 2019, Takeda America filed a pre-motion conference letter for a proposed motion for judgment on the pleadings on the grounds that Plaintiff’s claims are not plausibly pled and are also preempted. That same day, the other two defendants filed a pre-motion conference letter for a proposed motion to dismiss for lack of personal jurisdiction. (ECF Nos. 11–12.) On February 6, 2020, the Court waived its pre-motion conference requirement, set a briefing schedule, and

stayed all discovery. To date, no discovery has been conducted in this action. (Pl.’s Reply ¶ 31, ECF No. 27 at 9.) In violation of the Court’s briefing schedule, Defendants filed their motions on the docket on February 26, 2020. On March 12, 2020, an attorney filed a notice of appearance for Plaintiff. On March 26, 2020, Plaintiff—now represented by counsel—filed a motion to dismiss this action without prejudice. The Court stayed any further briefing on Defendants’ motions to dismiss. Plaintiff first retained counsel on November 27, 2019. On January 8, 2020, Plaintiff, represented by counsel, commenced a separate action in the New York state court against Dr. Lev Ginzburg and the affiliated NYU entities, alleging medical malpractice for the improper

administration of Entyvio to Plaintiff. (ECF No. 25 Ex. D.) Prior to the filing of Plaintiff’s motion to dismiss in this action, Plaintiff’s counsel and defense counsel attempted, but ultimately failed, to agree on the terms of a stipulation of dismissal for the instant suit. (ECF No. 25 at 3–4; ECF No. 26 at 3–4.) During those negotiations, Plaintiff sought a substantial settlement from Defendants. (ECF No. 26 at 4; Pl.’s Reply, ECF No. 27 at 1– 3.) Because Takeda America has already filed an answer, Plaintiff’s motion to dismiss seeks a dismissal without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(2). Defendants oppose Plaintiff’s motion, asserting that the Court should deny Plaintiff’s motion and rule on Defendants’ dispositive motions. In the alternative, Defendants ask the Court to impose two conditions on a dismissal: (1) a requirement that any refiling of Plaintiff’s claims occur in this Court; and (2) an award of attorney’s fees and costs to Defendants for defending this action. II. DISCUSSION A. Standard for Dismissal under Rule 41(a)(2)

Fed. R. Civ. P. 41(a)(2) provides that: “Except as provided in Rule 41(a)(1), an action may be dismissed at the plaintiff’s request only by court order, on terms that the court considers proper. . . . Unless the order states otherwise, a dismissal under [Rule 41(a)(2)] is without prejudice.” Although voluntary dismissal without prejudice is not a matter of right, courts in this circuit presume that a party’s motion to dismiss its own claims without prejudice should be granted.” Lopes v. First Unum Ins. Co., No. 09-CV-02642, 2012 WL 3887517, at *1 (E.D.N.Y. Sept. 7, 2012). In the Second Circuit, “[t]wo lines of authority have developed with respect to the circumstances under which a dismissal without prejudice might be improper.” Camilli v. Grimes,

436 F.3d 120, 123 (2d Cir. 2006). “One line indicates that such a dismissal would be improper if the defendant would suffer some plain legal prejudice other than the mere prospect of a second lawsuit.” Id. (internal quotation marks and citations omitted). “Another line indicates that the test for dismissal without prejudice involves consideration of various factors, known as the Zagano factors.” Id. (citing Zagano v. Fordham University, 900 F.2d 12, 14 (2d Cir. 1990)). The Zagano factors include: (1) plaintiff’s diligence in bringing a motion to dismiss; (2) any undue vexatiousness on plaintiff’s part; (3) the extent to which the suit has progressed, including defendant’s effort and expense in preparation for trial; (4) the duplicative expense of relitigation; and (5) the adequacy of plaintiff’s explanation for the need to dismiss. Zagano, 900 F.2d at 14. “These factors are not necessarily exhaustive and no one of them, singly or in combination with another, is dispositive.” Kwan v. Schlein, 634 F.3d 224, 230 (2d Cir. 2011). B. Analysis

Under either standard set forth above, the Court finds that Plaintiff should be permitted to dismiss this case without prejudice and without the imposition of any of the conditions requested by Defendants. Defendants’ primary argument is that Plaintiff’s request for an unconditional dismissal without prejudice should be denied because Plaintiff is engaging in forum-shopping. Specifically, Defendants maintain that Plaintiff seeks to dismiss this suit without prejudice so that Plaintiff can add Defendants to his state court action, which Defendants could not remove to federal court because complete diversity would be lacking. Plaintiff does not admit that he is engaging in potential forum-shopping. Instead, Plaintiff asserts that it is his “present intent . . . to pursue the Medical Malpractice Action, only” and that he does not “foresee that changing,” but seeks a discontinuance without prejudice “in the event that circumstances change or new facts come to

light.” (Pl.’s Reply ¶¶ 3, 16.) In support of their forum-shopping argument, Defendants rely on certain cases from outside the Second Circuit. (ECF No. 26 at 7.) However, courts in the Second Circuit “do not ordinarily consider potential forum shopping implications in deciding Rule 41(a)(2) motions” and have often granted plaintiffs’ requests for dismissals without prejudice even when the plaintiff is alleged to be engaged in forum shopping. Am. Fed’n of State, Cty. and Mun. Emps. v. Pfizer, Inc., No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kwan v. Schlein
634 F.3d 224 (Second Circuit, 2011)
Milton Lecompte v. Mr. Chip, Inc.
528 F.2d 601 (Fifth Circuit, 1976)
Nannette B. Davis v. Usx Corporation
819 F.2d 1270 (Fourth Circuit, 1987)
Scarlett Goodwin v. Dewight Reynolds
757 F.3d 1216 (Eleventh Circuit, 2014)
Stephan Bechuck v. Home Depot USA, Incorporated, e
814 F.3d 287 (Fifth Circuit, 2016)
Paysys Int'l, Inc. v. Atos It Servs. Ltd.
901 F.3d 105 (Second Circuit, 2018)
Ruth v. Purdue Pharma Co.
225 F.R.D. 434 (S.D. New York, 2004)
Colombrito v. Kelly
764 F.2d 122 (Second Circuit, 1985)

Cite This Page — Counsel Stack

Bluebook (online)
Spellman v. Takeda Development Center Americas, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/spellman-v-takeda-development-center-americas-inc-nyed-2021.